Beacon Pharmaceuticals

Beacon Pharmaceuticals Limited
Public
Traded as DSE: BEACONPHAR, CSE: BEACONPHAR
Industry Pharmaceutics
Biotechnology
Founded 2006 (2006)
Headquarters Dhaka, Bangladesh
Key people
 Md. Ebadul Karim (MD)
Products Sofosvel, Darvoni, Tagrix, Crizonix, Daclavir, Soforal
Number of employees
 2,000 (2015)
Website beaconpharma.com.bd

Beacon Pharmaceuticals Limited is a Bangladeshi pharmaceutical company that develops generic version of drug and commercializes therapeutics.

Beacon manufactures more than 200 generic drugs and 65 oncology products. In each year, Beacon is introducing more than 15-20 Hi-Tech new products. Beacon is the first company in Bangladesh to start export of cancer drugs.[1][2] The company is exporting its products in Asia, Africa and Latin America. After meeting the local demand, Beacon is exporting its medicine to many countries of Asia, Africa, Europe & Latin America. Beacon is public limited company listed in Dhaka & Chittagong stock exchange. About 2000 people are working in this company.;[3][4][5]

Beacon has introduced a number of global first generic.[6]

The company's current commercially available products include Velpatasvir/sofosbuvir, Sofosbuvir/Daclatasvir, Osimertinib, Crizotinib, Daclatasvir, Sofosbuvir.

References

  1. ↑ Chowdhury, Raihan M. (13 August 2012). "Bangladesh begins export of anti-cancer drugs". The Financial Express. Dhaka.
  2. ↑ "Anti-cancer drugs now made in Bangladesh". The Daily Star. 23 February 2010.
  3. ↑ Ahmed, Gazi Towhid (28 January 2015). "Beacon Pharma to invest Tk 290cr for expansion". The Daily Star.
  4. ↑ , Securities and Exchange Commission (Bangladesh)
  5. ↑ , Dhaka Stock Exchange
  6. ↑ Rajagopal, Divya (27 July 2016). "US' Gilead faces competition from Bangladesh's Beacon pharma". The Economic Times. Mumbai.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.